SINOVAC and Bogotá Present BogotáBio, Colombia's First Public Vaccine Manufacturing Facility

The company's launch ceremony was led by Sinovac's CEO and Chairman, Mr. Weidong Yin, alongside Bogotá's Mayor, Claudia López.

December 18, 2023, Bogotá, Colombia – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a renowned global provider of bio-pharmaceutical products, announced today its partnership with the District of Bogotá in establishing BogotáBio, a company focused on vaccine and biologics development and production, marking a significant milestone in the country's pursuit of health sovereignty.

The launch ceremony presided over by Sinovac's Chairman, President & CEO , Mr. Weidong Yin, and Bogotá's Mayor, Claudia López, marked the official start of this pioneering enterprise in Colombia. The company's incorporation was formalized, unveiling its corporate identity, symbolizing a steadfast commitment to public health and Colombia's technological and industrial advancement.

Mr. Yin noted that the COVID-19 pandemic has made all countries fully realize the importance of vaccines for national security and people's health and Bogotá Government made the choice of SINOVAC as a strategic partner came after evaluating proposals from 15 biopharmaceutical companies around the world. Bogotá Government and SINOVAC have formulated a 10-year development plan and will establish a vaccine production base which can produce multiple types of vaccines through technical cooperation."We will carry out project construction and personnel training in accordance with the most advanced international standards, in order to achieve localized production of vaccines in Colombia as soon as possible. We firmly believe that this project will benefit the people of Colombia."

Mayor López highlighted the collaboration's importance, emphasizing its contribution to scientific progress and independence in producing essential vaccines: "Thanks to the Chinese government and Sinovac for having trusted in Bogota, for believing in us and in Colombia. Thank you Mr. Yin for being here with us with your team. BogotáBio is a wonderful legacy that we leave to Colombia in terms of sanitary sovereignty".

BogotáBio: An Innovation and Progress Platform for Colombia

On May 31, 2023, following a rigorous selection process, Sinovac was appointed as the strategic partner for the District of Bogotá. This enterprise will not only manufacture vaccines against hepatitis A, varicella, and polio but will also develop capacities for future vaccines, preparing the country for forthcoming health emergencies, generating employment, and nurturing Colombian scientific talent.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd. 

PR Team 

pr@sinovac.com